Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
EW

EW - Edwards Lifesciences Corp Stock Price, Fair Value and News

$81.86-1.74 (-2.08%)
Market Closed

54/100

EW

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

54/100

EW

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$79.9

Target 3M

$82.74

Target 6M

$81.74

EW Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EW Price Action

Last 7 days

-3.8%

Last 30 days

-5.8%

Last 90 days

-1.9%

Trailing 12 Months

12.8%

EW RSI Chart

EW Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EW Valuation

Market Cap

47.5B

Price/Earnings (Trailing)

34.81

Price/Sales (Trailing)

8.07

EV/EBITDA

26.27

Price/Free Cashflow

59.07

EW Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$79.9

Target 3M

$82.74

Target 6M

$81.74

EW Fundamentals

EW Revenue

Revenue (TTM)

5.9B

Rev. Growth (Yr)

14.67%

Rev. Growth (Qtr)

1.36%

EW Earnings

Earnings (TTM)

1.4B

Earnings Growth (Yr)

-90.52%

Earnings Growth (Qtr)

-12.19%

EW Profitability

EBT Margin

26.73%

Return on Equity

13.37%

Return on Assets

10.28%

Free Cashflow Yield

1.69%

EW Investor Care

Buy Backs (1Y)

1.61%

Diluted EPS (TTM)

2.32

EW Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20255.5B5.7B5.9B0
20245.1B5.2B5.3B5.4B
20234.3B4.2B4.2B5.0B
20225.4B5.4B5.4B4.5B
20214.5B4.9B5.1B5.2B
20204.5B4.3B4.4B4.4B
20193.8B4.0B4.2B4.3B
20183.4B3.5B3.6B3.7B
20173.1B3.2B3.3B3.4B
20162.6B2.7B2.9B3.0B
20152.4B2.4B2.4B2.5B
20142.1B2.1B2.2B2.3B
20131.9B2.0B2.0B2.0B
20121.7B1.8B1.8B1.9B
20111.5B1.6B1.6B1.7B
20100001.4B
Get all data in R, Python etc through our Historical Stock Data APIs

About Edwards Lifesciences Corp

EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
 CEO
 WEBSITEedwards.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES17300

Edwards Lifesciences Corp Frequently Asked Questions

EW is the stock ticker symbol of Edwards Lifesciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Edwards Lifesciences Corp is 47.5 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check EW's fair value in chart for subscribers.

The fair value guage provides a quick view whether EW is over valued or under valued. Whether Edwards Lifesciences Corp is cheap or expensive depends on the assumptions which impact Edwards Lifesciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EW.

As of Wed Jan 28 2026, EW's PE ratio (Price to Earnings) is 34.81 and Price to Sales (PS) ratio is 8.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EW PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Edwards Lifesciences Corp has provided 0.121 (multiply by 100 for percentage) rate of return.